Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal
October 31 2023 - 1:26AM
Dow Jones News
By Adria Calatayud
Roche Holding said a late-stage trial evaluating its Elevidys
drug in Duchenne muscular dystrophy didn't reach its primary goal
of showing improvement in a measure of motor function.
The Swiss pharmaceutical giant said late Monday that it will
further analyze data from the trial, which evaluated its Elevidys
drug in boys aged 4-7 years with Duchenne muscular dystrophy who
could walk.
After 52 weeks of treatment, patients showed an improvement of
2.6 points on their North Star Ambulatory Assessment, a measure of
motor function, compared to 1.9 points in placebo-treated patients,
the company said.
Roche said the trial showed positive efficacy outcomes on
functional secondary goals such as time to rise from floor and
10-meter walk test.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 31, 2023 02:11 ET (06:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jan 2024 to Jan 2025
